METABOLISM OF IFOSFAMIDE DURING A 3 DAY INFUSION

被引:16
作者
HARTLEY, JM [1 ]
HANSEN, L [1 ]
HARLAND, SJ [1 ]
NICHOLSON, PW [1 ]
PASINI, F [1 ]
SOUHAMI, RL [1 ]
机构
[1] UCL, MIDDLESEX HOSP, SCH MED, DEPT MED ONCOL, LONDON W1N 8AA, ENGLAND
关键词
D O I
10.1038/bjc.1994.180
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Urinary drug metabolites were measured in 21 patients receiving ifosfamide by continuous infusion over 3 days. Mean values for the proportion of drug excreted as parent compound, 2-dechloroethylifosfamide (2-DC), 3-dechloroethylifosfamide (3-DC), carboxyifosfamide (CX) and ifosforamide mustard (IPM) were 19, 6, 10, 7 and 8% of dose respectively. The proportion of urinary drug products in the form of ifosfamide fell considerably over the course of the 3 days. This was mirrored by an increase in the proportion of 2-DC, 3-DC and CX. The proportion in the form of IPM, however, remained unchanged. With successive cycles the amount of 2-DC and IPM increased by about 10% per course. A very wide variation in the amount of each metabolite was reproducibly seen between patients, but no evidence for a genetic polymorphism was found. Urinary dechloroethyl metabolites correlated positively with each other and negatively with CX. Although autoinduction increases 'activation' of ifosfamide when given over 3 days, our evidence suggests that competing metabolic pathways prevent an increase in the amount of active metabolite formed.
引用
收藏
页码:931 / 936
页数:6
相关论文
共 19 条
  • [1] ALARCON RA, 1972, CANCER RES, V32, P2519
  • [2] COMBINED THIN-LAYER CHROMATOGRAPHY PHOTOGRAPHY DENSITOMETRY FOR THE QUANTIFICATION OF IFOSFAMIDE AND ITS PRINCIPAL METABOLITES IN URINE, CEREBROSPINAL-FLUID AND PLASMA
    BODDY, AV
    IDLE, JR
    [J]. JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1992, 575 (01): : 137 - 142
  • [3] BODDY AV, 1993, CANCER RES, V53, P3758
  • [4] STUDIES ON THE UROTOXICITY OF OXAZAPHOSPHORINE CYTOSTATICS AND ITS PREVENTION .2. COMPARATIVE-STUDY ON THE UROPROTECTIVE EFFICACY OF THIOLS AND OTHER SULFUR-COMPOUNDS
    BROCK, N
    POHL, J
    STEKAR, J
    [J]. EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1981, 17 (11): : 1155 - 1163
  • [5] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [6] SOME STUDIES OF ACTIVE INTERMEDIATES FORMED IN MICROSOMAL METABOLISM OF CYCLOPHOSPHAMIDE AND ISOPHOSPHAMIDE
    CONNORS, TA
    COX, PJ
    FARMER, PB
    FOSTER, AB
    JARMAN, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 1974, 23 (01) : 115 - 129
  • [7] GOREN MP, 1986, LANCET, V2, P1219
  • [8] HADIDI AHFA, 1988, CANCER RES, V48, P5167
  • [9] FRACTIONATED IFOSFAMIDE THERAPY PRODUCES A TIME-DEPENDENT INCREASE IN IFOSFAMIDE METABOLISM
    LEWIS, LD
    FITZGERALD, DL
    HARPER, PG
    ROGERS, HJ
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (05) : 725 - 732
  • [10] LIND MJ, 1989, CANCER RES, V49, P753